XURIDEN Drug Patent Profile
✉ Email this page to a colleague
When do Xuriden patents expire, and what generic alternatives are available?
Xuriden is a drug marketed by Btg Intl and is included in one NDA.
The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the uridine triacetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XURIDEN?
- What are the global sales for XURIDEN?
- What is Average Wholesale Price for XURIDEN?
Summary for XURIDEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Patent Applications: | 287 |
Drug Prices: | Drug price information for XURIDEN |
What excipients (inactive ingredients) are in XURIDEN? | XURIDEN excipients list |
DailyMed Link: | XURIDEN at DailyMed |
Pharmacology for XURIDEN
Ingredient-type | Analogs/Derivatives Pyrimidines |
Drug Class | Pyrimidine Analog |
US Patents and Regulatory Information for XURIDEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Btg Intl | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XURIDEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Btg Intl | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XURIDEN
See the table below for patents covering XURIDEN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2203669 | СПОСОБЫ ЛЕЧЕНИЯ СЕПСИСА И ВОСПАЛЕНИЙ С ПОМОЩЬЮ ОКСИПУРИНОВЫХ НУКЛЕОЗИДОВ (METHOD FOR TREATING SEPSIS AND INFLAMMATIONS DUE TO OXYPURINE NUCLEOSIDES) | ⤷ Sign Up |
Spain | 2160579 | ⤷ Sign Up | |
Japan | 2003160585 | OXYPURINE NUCLEOSIDE FOR IMPROVEMENT OF HEMATOPOIESIS, ITS HOMOLOG AND ITS ACRYL DERIVATIVE | ⤷ Sign Up |
Germany | 69635941 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XURIDEN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2207786 | 2023C/550 | Belgium | ⤷ Sign Up | PRODUCT NAME: CEDAZURIDINE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918 |
2207786 | 2023C/551 | Belgium | ⤷ Sign Up | PRODUCT NAME: UNE COMPOSITION COMPRENANT : DE LA CEDAZURIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ; ET LA DECITABINE; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918 |
1849470 | 2017/033 | Ireland | ⤷ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160425 |
1849470 | 300889 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |